ISSN 1214-0287 (on-line), ISSN 1214-021X (printed)
J Appl Biomed
Volume 11 (2013) No 1, p 7-13
DOI 10.2478/v10136-012-0015-x

Therapeutic efficacy of a novel bispyridinium oxime K203 and commonly used oximes (HI-6, obidoxime, trimedoxime, methoxime) in soman-poisoned male rats and mice

Jiri Kassa, Jana Zdarova Karasova, Marketa Krejciova

Address: Jiri Kassa, Faculty of Military Health Sciences, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic
kassa@pmfhk.cz

Received 12th March 2012.
Published online 2nd April 2012.

Full text article (pdf)
Full text article (html)

SUMMARY
The potency of a novel oxime K203 in reactivating soman-inhibited acetylcholinesterase and reducing acute toxicity of soman was compared with commonly used oximes (HI-6, obidoxime, trimedoxime, methoxime) using in vivo methods. The study determining percentage of reactivation of soman-inhibited blood and tissue acetylcholinesterase in rats showed that the potency of the oxime K203 to reactivate soman-inhibited acetycholinesterase in the peripheral compartment is slightly higher than obidoxime and trimedoxime, especially in the diaphragm, slightly lower than methoxime and markedly lower compared to the oxime HI-6. The reactivating efficacy of the oximes studied in the peripheral compartment roughly corresponds to their potency to reduce acute toxicity of soman in mice. Based on the obtained data, we can conclude that the oxime K203 is not suitable for the replacement of the oxime HI-6 for the antidotal treatment of acute soman poisoning due to its relatively low potency to counteract acute toxicity of soman.

KEY WORDS
soman; acetylcholinesterase; K203; HI-6; obidoxime; trimedoxime; methoxime; rats; mice

REFERENCES
Bajgar J. Organophosphate/nerve agent poisoning: mechanism of action, diagnosis, prophylaxis, and treatment. Adv Clin Chem. 38: 151-216, 2004.
[CrossRef]

Clement JG, Hansen AS, Boulet CA. Efficacy of HLo-7 and pyrimidoxime as antidotes of nerve agent poisoning in mice. Arch Toxicol. 66: 216-219, 1992.
[CrossRef] [PubMed]

Ekstrom F, Akfur C, Tunemalm AK, Lundberg S. Structural changes of phenylalanine 338 and histidine 447 revealed by the crystal structures of tabun-inhibited murine acetylcholinesterase. Biochemistry. 45: 74-81, 2006.
[CrossRef] [PubMed]

Ellman GL, Courtney DK, Andres V, Jr., Feartherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol. 7: 88-93, 1961.
[CrossRef]

Jokanovic M, Prostran M. Pyridinium oximes as cholinesterase reactivators. Structure-activity relationship and efficacy in the treatment of poisoning with organophosphorus compounds. Curr Med Chem. 16: 2177-2188, 2009.
[CrossRef] [PubMed]

Kassa J. Review of oximes in the antidotal treatment of poisoning by organophosphorus nerve agents. J Toxicol Clin Toxicol. 40: 803-816, 2002.
[CrossRef] [PubMed]

Kassa J, Cabal J. A comparison of the efficacy of a new asymmetric bispyridinium oxime BI-6 with currently available oximes and H oximes against soman by in vitro and in vivo methods. Toxicology. 132: 111-118, 1999.
[CrossRef]

Kassa J, Kuca K, Bartosova L, Kunesova G. The development of new structural analogues of oximes for the antidotal treatment of poisoning by nerve agents and the comparison of their reactivating and therapeutic efficacy with currently available oximes. Curr Org Chem. 11: 267-283, 2007.
[CrossRef]

Kassa J, Karasova J, Musilek K, Kuca K. An evaluation of therapeutic and reactivating effects of newly developed oximes (K156, K203) and commonly used oximes (obidoxime, trimedoxime, HI-6) in tabun-poisoned rats and mice. Toxicology. 243: 311-316, 2008.
[CrossRef] [PubMed]

Kovarik Z, Vrdoljak AL, Berend S, Katalinic M, Kuca K, Musilek K, Radic B. Evaluation of oxime K203 as antidote in tabun poisoning (in Croatian). Arh Hig Rada Toksikol. 60: 19-26, 2009.
[CrossRef] [PubMed]

Kuca K, Musilek K, Jun D, Pohanka M, Zdarova Karasova J, Novotny L, Musilova L. Could oxime HI-6 really be considered as "broad-spectrum" antidote? J Appl Biomed. 7: 143-149, 2009.
[JAB]

Lorke DE, Kalasz H, Petroianu GA, Tekes K. Entry of oximes into the brain: A review. Curr Med Chem. 15: 743-753, 2008.
[CrossRef] [PubMed]

Lotti M. Organophosphorus compounds. In Spencer PS, Schaumburg HH (eds.): Experimental and Clinical Neurotoxicology. Oxford University Press, New York 2000, pp. 898-925.

Lundy PM, Hand BT, Broxup BR, Yipchuck G, Hamilton MG. Distribution of the bispyridinium oxime [14C] HI-6 in male and female rats. Arch Toxicol. 64: 377-382, 1990.
[CrossRef] [PubMed]

Lundy PM, Raveh L, Amitai G. Development of the bisquaternary oxime HI-6 toward clinical use in the treatment of organophosphate nerve agent poisoning. Toxicol Rev. 25: 231-243, 2006.
[CrossRef] [PubMed]

Marrs TC, Rice P, Vale JA. The role of oximes in the treatment of nerve agent poisoning in civilian casualties. Toxicol Rev. 25: 297-323, 2006.
[CrossRef] [PubMed]

McDonough JR, Shih T-M. Neuropharmacological mechanisms of nerve agent - induced seizure and neuropathology. Neurosci Biobehav Rev. 21: 559-579, 1997.
[CrossRef]

Musilek K, Holas O, Kuca K, Jun D, Dohnal V, Opletalova V, Dolezal M. Synthesis of monooxime-monocarbamoyl bispyridinium compounds bearing (E)-but-2-ene linker and evaluation of their reactivation activity against tabun- and paraoxon-inhibited acetylcholinesterase. J Enzyme Inhib Med Chem. 23: 70-76, 2008.
[CrossRef] [PubMed]

Puu G, Artursson E, Bucht G. Reactivation of nerve agent inhibited acetylcholinesterases by HI-6 and obidoxime. Biochem Pharmacol. 35: 1505-1510, 1986.
[CrossRef]

Shih T-M. Comparison of several oximes on reactivation of soman-inhibited blood, brain and tissue cholinesterase activity in rats. Arch Toxicol. 67: 637-646, 1993.
[CrossRef] [PubMed]

Szinicz L, Worek F, Thiermann H, Kehe K, Eckert S, Eyer P. Development of antidotes: problems and strategies. Toxicology. 233: 23-30, 2007.
[CrossRef] [PubMed]

Tallarida R, Murray R. Manual of Pharmacological Calculation with Computer Programs. Springer-Verlag, New York 1987.

Tryphonas L, Clement JG. Histomorphogenesis of soman-induced encephalocardio- myopathy in Sprangue-Dawley rats. Toxicol Pathol. 23: 393-397, 1995.
[CrossRef] [PubMed]

van Helden HPM, Busker RW, Melchers BPC, Bruijnzeel PLB. Pharmacological effects of oximes: how relevant are they? Arch Toxicol. 70: 779–786, 1996.
[CrossRef] [PubMed]

Worek F, Widmann R, Knopff O, Szinicz L. Reactivating potency of obidoxime, pralidoxime, HI-6 and HLo-7 in human erythrocyte acetylcholinesterase inhibited by highly toxic organophosphorus compounds. Arch Toxicol. 72: 237-243, 1998.
[CrossRef] [PubMed]

Zdarova Karasova J, Zemek F, Bajgar J, Vasatova M, Prochazka P, Novotny L, Kuca K. Partition of bispyridinium oximes (trimedoxime, K074) administered in therapeutic doses into different parts of the rat brain. J Pharm Biomed Anal. 54: 1082-1087, 2011.
[CrossRef] [PubMed]
CITED

0


BACK